Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBCBS Tennessee Leuprolide Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - TennesseePolicy ID_CHS_60512026a_0926

    Leuprolide Acetate Depot Suspension (Lupron Depot-Ped®)

    Customize your policy alerts

    Sign up for blue cross blue shield - tennessee Policy ID_CHS_60512026a_0926 alerts

    Get alerted when Policy ID_CHS_60512026a_0926 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy establishes prior authorization and medical necessity criteria for leuprolide acetate depot suspension for pediatric central precocious puberty and gender-affirming care, including clinical, documentation, and prescriber requirements.

    Policy Summary
    PayerBlue Cross Blue Shield - Tennessee
    PolicyLeuprolide Acetate Depot Suspension (Lupron Depot-Ped®)
    Policy CodePolicy ID_CHS_60512026a_0926
    Change TypeNo material change
    Effective DateDecember 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization requests with the required clinical documentation for coverage review.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2Covered indication categories
    12 monthsInitial authorization period
    Tanner 2+Puberty threshold for gender-affirming suppression
    Not coveredOther indications

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    12 months
    Continued gender-transition authorization

    Covered and Noncovered Indications

    Initial Therapy: Central Precocious Puberty

    Authorization of 12 months may be granted for treatment of central precocious puberty (CPP) when <strong>all</strong> of the following criteria are met:

    ALL of the following

    • ONE of the following diagnostic criteria

      • A pubertal response to a gonadotropin-releasing hormone (GnRH) agonist test, based on the laboratory reference range.
      • A pubertal basal level of luteinizing hormone (LH) on a third-generation LH assay, based on the laboratory reference range.
    • ONE of the following member criteria

      • The assessment of bone age versus chronological age supports the diagnosis of CPP.
      • The member is female and was less than 8 years of age at the onset of secondary sexual characteristics.
      • The member is male and was less than 9 years of age at the onset of secondary sexual characteristics.
    • The pathologic cause of CPP has been assessed, such as imaging screening for intracranial tumors or genetic testing for familial CPP (e.g., MKRN3 or DLK1 variants).

    Initial Therapy: Gender-Affirming Pubertal Suppression

    Authorization of 12 months may be granted for pubertal hormonal suppression in an adolescent member seeking gender-affirming care when <strong>all</strong> of the following criteria are met. The individual must be age 18 or older, or less than age 18 as permissive under applicable law.

    ALL of the following

    • The member is able to make an informed decision to engage in treatment.
    • The member has a diagnosis of gender dysphoria.
    • The member has reached Tanner stage 2 of puberty or greater.
    • The member has been educated on any contraindications and side effects to therapy.
    • The member's comorbid conditions are reasonably controlled.

    Initial Therapy: Gender Transition

    Authorization of 12 months may be granted for gender transition in a member seeking gender-affirming care when <strong>all</strong> of the following criteria are met. The individual must be age 18 or older, or less than age 18 as permissive under applicable law.

    ALL of the following

    • The member is able to make an informed decision to engage in treatment.
    • The member has a diagnosis of gender dysphoria.
    • The member will receive the requested medication concomitantly with gender-affirming hormones.
    • The member has been educated on any contraindications and side effects to therapy.
    • The member's comorbid conditions are reasonably controlled.

    Continuation Therapy: Central Precocious Puberty

    Authorization of up to 12 months may be granted for continued treatment of CPP when <strong>both</strong> of the following criteria are met:

    ALL of the following

    • The member is not experiencing treatment failure, such as clinical pubertal progression, lack of growth deceleration, or continued excessive bone age advancement.
    • The member is ONE of the following

      • Female and less than 12 years of age.
      • Male and less than 13 years of age.

    Continuation Therapy: Gender-Affirming Pubertal Suppression

    Authorization of 12 months may be granted for continued treatment for pubertal hormonal suppression in an adolescent member seeking gender-affirming care and requesting reauthorization when <strong>all</strong> of the following criteria are met. The individual must be age 18 or older, or less than age 18 as permissive under applicable law.

    ALL of the following

    • The member is able to make an informed decision to engage in treatment.
    • The member has a diagnosis of gender dysphoria.
    • The member has previously reached Tanner stage 2 of puberty or greater.
    • The member's comorbid conditions are reasonably controlled.
    • The member has been educated on any contraindications and side effects to therapy.

    Continuation Therapy: Gender Transition

    Authorization of 12 months may be granted for continued treatment for gender transition in a member seeking gender-affirming care and requesting reauthorization when <strong>all</strong> of the following criteria are met. The individual must be age 18 or older, or less than age 18 as permissive under applicable law.

    ALL of the following

    • The member is able to make an informed decision to engage in treatment.
    • The member has a diagnosis of gender dysphoria.
    • The member will receive the requested medication concomitantly with gender-affirming hormones.
    • The member has been educated on any contraindications and side effects to therapy.
    • The member's comorbid conditions are reasonably controlled.

    Gender dysphoria, also known as transgender and gender diverse (TGD) persons, is a compendial use. All other indications are considered experimental/investigational and not medically necessary.

    Leuprolide acetate depot suspension is not medically necessary for indications other than listed FDA-approved or compendial uses.

    Initial Authorization Requirements

    Central Precocious Puberty: Initial 12-Month Authorization

    Authorization of 12 months may be granted for treatment of central precocious puberty when all of the following criteria are met.

    CPP initial therapy

    • Diagnostic confirmation

      • A pubertal response to a gonadotropin-releasing hormone agonist test is documented.
      • A pubertal basal luteinizing hormone level on a third-generation assay is documented.
    • Supporting CPP criterion

      • Assessment of bone age versus chronological age supports the diagnosis of central precocious puberty.
      • Age at onset

    Continued Authorization Requirements

    Central Precocious Puberty: Continued Treatment

    Authorization of up to 12 months may be granted for continued treatment of central precocious puberty when both criteria are met.

    CPP continuation: The member is not experiencing treatment failure and is either a female less than 12 years of age or a male less than 13 years of age.Female <12 years; male <13 years

    Treatment failure includes clinical pubertal progression, lack of growth deceleration, or continued excessive bone age advancement.

    Gender Dysphoria: Continued Gender-Affirming Treatment

    Authorization of 12 months may be granted for continued gender-affirming treatment when all of the following criteria are met.

    Gender-affirming continuation: For pubertal suppression, the member must be able to make an informed decision, have gender dysphoria, have previously reached Tanner stage 2 or greater, have reasonably controlled comorbid conditions, have received education about contraindications and side effects, and have been informed of fertility preservation options before therapy. For gender transition, the member must also receive the medication concomitantly with gender-affirming hormones.

    Authorization, Documentation, and Denial Risks

    Prior Authorization

    Prior Authorization and Clinical Evidence

    Prior authorization is required for covered use of leuprolide acetate depot suspension. The request must include the applicable clinical evidence for the requested indication, including the documentation required for initial central precocious puberty (CPP) review.

    • Covered indications are subject to all applicable approval criteria and member benefit exclusions.
    • For initial CPP requests, submit documentation of a pubertal response to a GnRH agonist test or a pubertal basal LH level on a third-generation LH assay.
    Prior Authorization

    12-Month Continuation Authorization

    Reauthorization may be granted for 12 months for continued pubertal hormonal suppression or gender-transition treatment when all applicable continuation criteria are met.

    • For continued pubertal hormonal suppression, the member must be able to make an informed treatment decision, have gender dysphoria, have previously reached Tanner stage 2 or greater, and have reasonably controlled comorbid conditions.

    Therapy and Policy Context

    Lupron Depot-PED is leuprolide acetate depot therapy used for pediatric central precocious puberty. The policy also recognizes gender dysphoria, including transgender and gender-diverse persons, as a compendial use for pubertal hormonal suppression or gender transition when the applicable clinical, counseling, and prescribing requirements are met.

    Clinical Definitions

    Central precocious puberty (CPP)
    DefinitionEarly activation of puberty, or central precocious puberty (CPP).
    Diagnostic confirmationConfirm CPP using laboratory reference ranges with either a pubertal response to a gonadotropin-releasing hormone (GnRH) agonist test or a pubertal basal luteinizing hormone (LH) level on a third-generation LH assay.
    Supporting evidenceEither bone-age assessment compared with chronological age supports the diagnosis, or the age-at-onset criterion is met: female younger than 8 years or male younger than 9 years at onset of secondary sexual characteristics.
    Etiologic assessmentThe pathologic cause of CPP must be assessed, including evaluation such as imaging for intracranial tumors or genetic testing for familial CPP when applicable.
    Gender dysphoria
    Policy definition
    Policy Summary
    PayerBlue Cross Blue Shield - Tennessee
    PolicyLeuprolide Acetate Depot Suspension (Lupron Depot-Ped®)
    Policy CodePolicy ID_CHS_60512026a_0926
    Change TypeNo material change
    Effective DateDecember 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization requests with the required clinical documentation for coverage review.
    SourceLink
    On This Page
    Covered and Noncovered IndicationsInitial Authorization RequirementsContinued Authorization RequirementsAuthorization, Documentation, and Denial RisksTherapy and Policy ContextClinical Definitions
    The member has been informed of fertility preservation options.
    The member has been informed of fertility preservation options.
  1. Before the start of therapy, the member has been informed of fertility preservation options.
  2. Before the start of therapy, the member has been informed of fertility preservation options.
    • The member was female and less than 8 years of age at onset of secondary sexual characteristics.<8 years
    • The member was male and less than 9 years of age at onset of secondary sexual characteristics.<9 years
  3. The pathologic cause of central precocious puberty has been assessed, such as through imaging screening for intracranial tumors or genetic testing for familial central precocious puberty, including MKRN3 or DLK1 variants.
  4. Gender-Affirming Pubertal Suppression: Initial 12-Month Authorization

    Authorization of 12 months may be granted for pubertal hormonal suppression in an adolescent member seeking gender-affirming care when all of the following criteria are met.

    Gender-affirming pubertal suppression: The member is able to make an informed decision to engage in treatment; has a diagnosis of gender dysphoria; has reached Tanner stage 2 or greater; has received education about contraindications and side effects; has reasonably controlled comorbid conditions; and has been informed of fertility preservation options.Tanner stage 2 or greater

    The individual must be age 18 or older or younger than 18 as permissive under applicable law.

    Gender Transition: Initial Authorization

    Authorization of 12 months may be granted for gender transition in a member seeking gender-affirming care when all of the following criteria are met.

    Gender transition: The member is able to make an informed decision to engage in treatment; has a diagnosis of gender dysphoria; will receive the requested medication concomitantly with gender-affirming hormones; has received education about contraindications and side effects; has reasonably controlled comorbid conditions; and has been informed of fertility preservation options.Concomitant gender-affirming hormones

    The individual must be age 18 or older or younger than 18 as permissive under applicable law.

    Tanner stage 2+; concomitant gender-affirming hormones for transition

    The individual must be age 18 or older or younger than 18 as permissive under applicable law.

    12-Month Continuation Authorization: Gender Transition

    Authorization of 12 months may be granted for continued treatment for gender transition when all of the following criteria are met.

    12-month continuation authorization: The member is able to make an informed decision to engage in treatment; has a diagnosis of gender dysphoria; will receive the requested medication concomitantly with gender-affirming hormones; has been educated on contraindications and side effects; has reasonably controlled comorbid conditions; and, before the start of therapy, was informed of fertility preservation options.
  5. For continued gender-transition treatment, the member must be able to make an informed treatment decision, have gender dysphoria, receive the medication concomitantly with gender-affirming hormones, and have reasonably controlled comorbid conditions.
  6. For either continuation indication, required education regarding contraindications and side effects must be documented; fertility-preservation counseling must have occurred before therapy began.
  7. Documentation Required

    CPP Diagnostic Documentation

    For an initial CPP request, submit a laboratory report or medical-record documentation confirming a pubertal response to a GnRH agonist test or a pubertal basal LH level on a third-generation LH assay.

    • The CPP diagnosis must be confirmed using the applicable laboratory reference range.
    Documentation Required

    Gender Dysphoria Provider Documentation

    For gender dysphoria, leuprolide must be prescribed by or in consultation with a provider specialized in the care of transgender youth. For members younger than 18, the provider must have collaborated care with a mental health provider.

    • Examples of specialized providers include a pediatric endocrinologist, family or internal medicine physician, or obstetrician-gynecologist.
    • Document the specialty provider involvement and, when applicable, collaboration with a mental health provider.
    Documentation Required

    Continuation Treatment Documentation

    Continuation requests must document the member's ongoing eligibility and treatment requirements for the applicable indication. The record must support informed decision-making, the diagnosis of gender dysphoria, appropriate medication use, and required counseling and safety assessments.

    • Document that the member is able to make an informed decision to engage in treatment and continues to have a diagnosis of gender dysphoria.
    • For continued pubertal hormonal suppression, document that the member previously reached Tanner stage 2 or greater.
    • For continued gender transition, document concomitant use of gender-affirming hormones.
    • Document education on contraindications and side effects and that comorbid conditions are reasonably controlled.
    • Document that fertility-preservation options were discussed before the start of therapy.

    Unsupported block type: denial_risk

    Denial Risk

    CPP Criteria Not Met

    A CPP request may be denied when the diagnosis is not confirmed or when required clinical evidence is missing.

    • The request must document either a pubertal response to a GnRH agonist test or a pubertal basal LH level on a third-generation LH assay, based on the applicable laboratory reference range.
    • The request must support the CPP diagnosis through bone-age assessment relative to chronological age and applicable age-of-onset criteria: female members younger than 8 at onset of secondary sexual characteristics or male members younger than 9 at onset.
    • The pathologic cause of CPP must be assessed, such as through imaging screening for intracranial tumors or genetic testing for familial CPP, including MKRN3 or DLK1 variants.
    Denial Risk

    Gender-Affirming Criteria Not Met

    A gender-affirming treatment request may be denied when any required clinical criterion is not met for the requested initial or continuation therapy.

    • The member must be able to make an informed decision to engage in treatment and have a diagnosis of gender dysphoria.
    • For initial pubertal hormonal suppression, the member must have reached Tanner stage 2 or greater; for continuation, the member must have previously reached Tanner stage 2 or greater.
    • For gender transition, the requested medication must be used concomitantly with gender-affirming hormones.
    • The member must be educated on contraindications and side effects, have reasonably controlled comorbid conditions, and be informed of fertility-preservation options before therapy begins.
    Documentation Required

    Prescriber Specialty Requirement

    The medication must be prescribed by or in consultation with a provider specialized in transgender youth care. Missing specialty involvement or required mental-health collaboration can prevent authorization.

    • Acceptable examples include a pediatric endocrinologist, family or internal medicine physician, or obstetrician-gynecologist with expertise in transgender youth care.
    • For members younger than 18, the specialized provider must have collaborated care with a mental health provider.
    Denial Risk

    Failure to Meet Continuation Criteria

    Failure to satisfy any applicable continuation criterion creates a risk of denial for reauthorization. The continuation request must support the member's current clinical status and ongoing treatment plan.

    • Denial risk includes inability to make an informed treatment decision, no documented diagnosis of gender dysphoria, or failure to meet the applicable Tanner-stage requirement.
    • For gender-transition reauthorization, denial risk includes lack of concomitant gender-affirming hormones.
    • Denial risk also includes uncontrolled comorbid conditions, missing education regarding contraindications or side effects, or missing documentation that fertility-preservation options were discussed before therapy began.
    Note

    State Age Restrictions

    State regulatory guidelines concerning gender dysphoria may impose age restrictions. Confirm that the member's age and treatment are permissible under applicable Tennessee law before submitting or renewing authorization.

    • The policy states that an individual must be age 18 or older, or younger than 18 as permissive under applicable law, for the listed gender-affirming authorization criteria.
    Gender dysphoria, also described as transgender and gender diverse (TGD) persons, is a compendial indication recognized by the policy.
    Compendial useLeuprolide may be used for pubertal hormonal suppression or gender transition in a member seeking gender-affirming care when the policy criteria are met.
    Pubertal suppression thresholdFor pubertal hormonal suppression, the member must have reached Tanner stage 2 of puberty or greater.
    Gender-transition requirementFor gender transition, the requested medication must be received concomitantly with gender-affirming hormones.
    Additional requirementsThe member must be able to make an informed decision, have reasonably controlled comorbid conditions, receive education about contraindications and side effects, and be informed of fertility-preservation options.